BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 30344087)

  • 1. Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models.
    Ilg MM; Mateus M; Stebbeds WJ; Milenkovic U; Christopher N; Muneer A; Albersen M; Ralph DJ; Cellek S
    Eur Urol; 2019 Feb; 75(2):329-340. PubMed ID: 30344087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie's Disease.
    Ilg MM; Stafford SJ; Mateus M; Bustin SA; Carpenter MJ; Muneer A; Bivalacqua TJ; Ralph DJ; Cellek S
    J Sex Med; 2020 Oct; 17(10):1848-1864. PubMed ID: 32771352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins synergize with phosphodiesterase type 5 inhibitors but not with selective estrogen receptor modulators to prevent myofibroblast transformation in an in vitro model of Peyronie's disease.
    Ilg MM; Ralph DJ; Cellek S
    J Sex Med; 2023 Jun; 20(7):925-934. PubMed ID: 37082866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures.
    Valente EG; Vernet D; Ferrini MG; Qian A; Rajfer J; Gonzalez-Cadavid NF
    Nitric Oxide; 2003 Dec; 9(4):229-44. PubMed ID: 14996430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy.
    Gonzalez-Cadavid NF; Rajfer J
    Nat Rev Urol; 2010 Apr; 7(4):215-21. PubMed ID: 20212516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the Role of Adenosine Receptors in the Myofibroblast Transformation in Peyronie's Disease.
    Mateus M; Ilg MM; Stebbeds WJ; Christopher N; Muneer A; Ralph DJ; Cellek S
    J Sex Med; 2018 Jul; 15(7):947-957. PubMed ID: 29891411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental models of Peyronie's disease. Implications for new therapies.
    Gonzalez-Cadavid NF; Rajfer J
    J Sex Med; 2009 Feb; 6(2):303-13. PubMed ID: 19138365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model.
    Vernet D; Ferrini MG; Valente EG; Magee TR; Bou-Gharios G; Rajfer J; Gonzalez-Cadavid NF
    Nitric Oxide; 2002 Dec; 7(4):262-76. PubMed ID: 12446175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combination of phosphodiesterase type 5 inhibitor and tamoxifen for acute Peyronie's disease: the first clinical signals.
    Cellek S; Megson M; Ilg MM; Ralph DJ
    J Sex Med; 2023 Jul; 20(8):1057-1059. PubMed ID: 37524687
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease.
    Ferrini MG; Kovanecz I; Nolazco G; Rajfer J; Gonzalez-Cadavid NF
    BJU Int; 2006 Mar; 97(3):625-33. PubMed ID: 16469038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The transcriptional signatures of cells from the human Peyronie's disease plaque and the ability of these cells to generate a plaque in a rat model suggest potential therapeutic targets.
    Gelfand RA; Vernet D; Kovanecz I; Rajfer J; Gonzalez-Cadavid NF
    J Sex Med; 2015 Feb; 12(2):313-27. PubMed ID: 25496134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie's disease.
    Ilg MM; Lapthorn AR; Ralph DJ; Cellek S
    PLoS One; 2022; 17(12):e0277646. PubMed ID: 36508413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in Peyronie's-like plaque size using a vacuum erection device in a rat model of Peyronie's disease via the TGF-β/SMAD signalling pathway.
    Li J; Wang S; Qin F; Zhu M; You X; Wu C; Fu F; Yuan J
    Andrologia; 2018 Sep; 50(7):e13051. PubMed ID: 29806152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transforming growth factor (TGF)-β type I receptor kinase (ALK5) inhibitor alleviates profibrotic TGF-β1 responses in fibroblasts derived from Peyronie's plaque.
    Piao S; Choi MJ; Tumurbaatar M; Kim WJ; Jin HR; Shin SH; Tuvshintur B; Yin GN; Song JS; Kwon MH; Lee SJ; Han JY; Kim SJ; Ryu JK; Suh JK
    J Sex Med; 2010 Oct; 7(10):3385-95. PubMed ID: 20233292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie's disease.
    Davila HH; Ferrini MG; Rajfer J; Gonzalez-Cadavid NF
    BJU Int; 2003 Jun; 91(9):830-8. PubMed ID: 12780843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temporal gene signature of myofibroblast transformation in Peyronie's disease: first insights into the molecular mechanisms of irreversibility.
    Ilg MM; Harding S; Lapthorn AR; Kirvell S; Ralph DJ; Bustin SA; Ball G; Cellek S
    J Sex Med; 2024 Mar; 21(4):278-287. PubMed ID: 38383071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pentoxifylline attenuates transforming growth factor-β1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix.
    Shindel AW; Lin G; Ning H; Banie L; Huang YC; Liu G; Lin CS; Lue TF
    J Sex Med; 2010 Jun; 7(6):2077-2085. PubMed ID: 20367772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The two phases of the clinical validation of preclinical translational mechanistic research on PDE5 inhibitors since Viagra's advent. A personal perspective.
    Gonzalez-Cadavid NF; Rajfer J
    Int J Impot Res; 2019 Mar; 31(2):57-60. PubMed ID: 30258189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie's Disease.
    Milenkovic U; Ilg MM; Cellek S; Albersen M
    Sex Med Rev; 2019 Oct; 7(4):679-689. PubMed ID: 30962046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IN-1130, a novel transforming growth factor-beta type I receptor kinase (activin receptor-like kinase 5) inhibitor, promotes regression of fibrotic plaque and corrects penile curvature in a rat model of Peyronie's disease.
    Ryu JK; Piao S; Shin HY; Choi MJ; Zhang LW; Jin HR; Kim WJ; Han JY; Hong SS; Park SH; Lee SJ; Kim IH; Lee CR; Kim DK; Mamura M; Kim SJ; Suh JK
    J Sex Med; 2009 May; 6(5):1284-96. PubMed ID: 19473283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.